Download PDF
CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2017; 04(01): 004-009
DOI: 10.4103/2348-0548.197431
Review Article
Thieme Medical and Scientific Publishers Private Ltd.

Pharmacogenomics of neuropathic pain

Vandana Sharma
1   Department of Anesthesiology, Upstate Medical University, State University of New York Upstate, New York 13210, USA
,
Munish › Author Affiliations
Further Information

Publication History

Publication Date:
05 May 2018 (online)

   Permissions and Reprints

Abstract

Variation in pain sensitivity and analgesic drug response is well recognized among individuals. Pharmacogenomics hypothesis dictates that a patient’s response to a drug or development of adverse drug effects may depend on variation in genetic profile, in particular, the different alleles for the same gene that an individual carries. A review of the role of genetic variations in determining the receptor sensitivity and modulation of pain, response to analgesics drugs and their interactions are presented in this article. It is already known that genomic variations affect the pharmacokinetic and pharmacodynamic properties of various analgesic drugs. Genes related to the expression of mu-opioid receptor, ATP- binding cassette B1 (ABCB1), catechol-O-Methyl Transferase (COMT), Cytochrome P450 enzymes have been widely studied and show some promise in determining the drug response in individuals. Some recent studies on sodium channel mutations (SCN9A, SCN11A) have been implicated in congenital insensitivity to pain. Voltage gated ion channels such as sodium, calcium and potassium channels are being targeted for development of novel analgesics. Based on the available research, the clinical implementation of pharmacogenomics for personalized pain medicine is still in its infancy, but is promising. These are opening further opportunities for development of newer analgesics targeting pain receptors and ion channels.

Keywords

Genetics - neuropathic pain - pharmacogenetics - pharmacogenomics
 

  • REFERENCES

  • 1 Sadhasivam S, Chidambaran V, Olbrecht VA, Esslinger HR, Zhang K, Zhang X. et al. Genetics of pain perception, COMT and postoperative pain management in children. Pharmacogenomics 2014; 15: 277-84
    CrossrefPubMedGoogle Scholar
  • 2 Nishizawa D, Fukuda K, Kasai S, Hasegawa J, Aoki Y, Nishi A. et al. Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Mol Psychiatry 2014; 19: 55-62
    CrossrefPubMedGoogle Scholar
  • 3 Zahari Z, Ismail R. Impact of opioid receptor, Mu 1 (OPRM1) polymorphisms on pain sensitivity and clinical response to opioid analgesic therapy. Curr Pharmacogenomics Pers Med 2013; 11: 59-75
    PubMedGoogle Scholar
  • 4 Rode F, Thomsen M, Broløs T, Jensen DG, Blackburn-Munro G, Bjerrum OJ. The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain. Eur J Pharmacol 2007; 564: 103-11
    CrossrefPubMedGoogle Scholar
  • 5 Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: Impact of genetic polymorphism. Mol Diagn Ther 2008; 12: 109-24
    CrossrefPubMedGoogle Scholar
  • 6 Tricyclic antidepressant dosing recommendations based on CYP2D6 and CYP2C19 Genotypes. Pharmacogenomics 2013; 14: 1379-80
    PubMedGoogle Scholar
  • 7 Chesler EJ, Ritchie J, Kokayeff A, Lariviere WR, Wilson SG, Mogil JS. Genotype-dependence of gabapentin and pregabalin sensitivity: The pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 2003; 106: 325-35
    CrossrefPubMedGoogle Scholar
  • 8 Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G. et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-33
    CrossrefPubMedGoogle Scholar
  • 9 Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S. et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-8
    CrossrefPubMedGoogle Scholar
  • 10 Fernandez Robles CR, Degnan M, Candiotti KA. Pain and genetics. Curr Opin Anaesthesiol 2012; 25: 444-9
    CrossrefPubMedGoogle Scholar
  • 11 Gürsoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003; 23: 104-7
    CrossrefPubMedGoogle Scholar
  • 12 Andersen S, Skorpen F. Variation in the COMT gene: Implications for pain perception and pain treatment. Pharmacogenomics 2009; 10: 669-84
    CrossrefPubMedGoogle Scholar
  • 13 Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y. et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299: 1240-3
    CrossrefPubMedGoogle Scholar
  • 14 Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: Evidence from a meta-analysis. Pharmacogenomics 2013; 14: 813-24
    CrossrefPubMedGoogle Scholar
  • 15 Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146: 270-5
    CrossrefPubMedGoogle Scholar
  • 16 Walter C, Doehring A, Oertel BG, Lötsch J. μ-opioid receptor gene variant OPRM1 118 A>G: A summary of its molecular and clinical consequences for pain. Pharmacogenomics 2013; 14: 1915-25
    CrossrefPubMedGoogle Scholar
  • 17 Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9
    CrossrefPubMedGoogle Scholar
  • 18 Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg 2011; 112: 448-53
    CrossrefPubMedGoogle Scholar
  • 19 Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92: 1392-9
    CrossrefPubMedGoogle Scholar
  • 20 Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M. et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002; 54: 592-603
    PubMedGoogle Scholar
  • 21 Candiotti K, Yang Z, Xue L, Zhang Y, Rodriguez Y, Wang L. et al. Single-nucleotide polymorphism C3435T in the ABCB1 gene is associated with opioid consumption in postoperative pain. Pain Med 2013; 14: 1977-84
    CrossrefPubMedGoogle Scholar
  • 22 Lee MG, Kim HJ, Lee KH, Choi YS. The influence of genotype polymorphism on morphine analgesic effect for postoperative pain in children. Korean J Pain 2016; 29: 34-9
    CrossrefPubMedGoogle Scholar
  • 23 Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559-66
    CrossrefPubMedGoogle Scholar
  • 24 Norbury TA, MacGregor AJ, Urwin J, Spector TD, McMahon SB. Heritability of responses to painful stimuli in women: A classical twin study. Brain 2007; 130 (Pt 11) 3041-9
    CrossrefPubMedGoogle Scholar
  • 25 Chen YC, Auer-Grumbach M, Matsukawa S, Zitzelsberger M, Themistocleous AC, Strom TM. et al. Transcriptional regulator PRDM12 is essential for human pain perception. Nat Genet 2015; 47: 803-8
    CrossrefPubMedGoogle Scholar
  • 26 Smith MT, Muralidharan A. Pharmacogenetics of pain and analgesia. Clin Genet 2012; 82: 321-30
    CrossrefPubMedGoogle Scholar
  • 27 Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006; 11: 126-35
    CrossrefPubMedGoogle Scholar
  • 28 Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402-8
    CrossrefPubMedGoogle Scholar
  • 29 Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84: 613-24
    CrossrefPubMedGoogle Scholar
  • 30 Yiannakopoulou E. Pharmacogenomics and opioid analgesics: Clinical implications. Int J Genomics 2015; 2015: 368979
    PubMedGoogle Scholar
  • 31 Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O. et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353-6
    CrossrefPubMedGoogle Scholar
  • 32 Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008; 83: 200-2
    CrossrefPubMedGoogle Scholar
  • 33 Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S. et al. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther 2013; 345: 297-307
    CrossrefPubMedGoogle Scholar